April 28, Stockholm, Sweden The Caroline Institute of Sweden released a report on the 28th that the hospital will begin the human comparison test of anti-nicotine vaccine in three countries in northern Europe next year. The vaccine is designed to help smokers to stop smoking.
According to a Swedish media report, after 10 years of research and development, researchers from the Caroline Institute have developed this anti-nicotine vaccine under the leadership of the founder of the Swedish independent pharmaceutical company Tony Svenson, and named it as a "negative vaccine."
According to the report, theoretically, if a smoker who received a "Nigeria vaccine" smokes, the antibody produced by his vaccine will react and lock the nicotine produced by smoking so that it will not affect the brain-sensing system. Therefore, it is impossible to create a sense of pleasure for making smokers addicted. However, there is a key problem in the current research and development of nicotine vaccine: under normal circumstances, the human immune system will not respond to nicotine.
In order to activate the immune system, the nicotine in the vaccine needs to be locked in a "parent" that stimulates the immune system so that it can produce as many antibodies as possible. This "maternal" contains nicotine but is not addictive. It is a key component of the "neon vaccine."
The report quoted Leona Vikingson, head of the independent pharmaceutical company, as saying that 400 of the testers were all heavy nicotine dependents who wanted to quit smoking. These people will first receive psychological counseling and take drugs before quitting smoking. For the next four months, researchers will inject half of the testers with an anti-nicotine vaccine once a month and the other half with a placebo. Researchers will observe whether or not the test taker relapses in the next 1 year.
Guangzhou Jointair Co., Ltd. , https://www.nbjointair.com